Thank you for being part of India Rising. It’s great to have you here!

This is the third issue of our very first India Rising Perspective! I’m super excited to share this series with you, and thankful for the contribution by our authors from Guidance Tamil Nadu.

Learned something? Help someone else and share India Rising with your friends, family and co-workers. Let’s grow our community together and thank you for supporting the Indo-European partnership.

Got feedback? Just hit reply, I’d love to hear from you!

India's story of becoming the world's 3rd largest economy isn't one single narrative. It's being written by its powerful, fast-moving states as well. Tamil Nadu embodies this ambition, targeting a $1 trillion economy by 2030. This requires a world-class strategy to attract global investment, build future-ready infrastructure, and foster deep innovation.

To understand this playbook, we want to understand it directly from the source. As our authors are from the state's official, UN-award-winning nodal agency, Guidance Tamil Nadu is the architect and driver of this mission.

In this series, Godson George Micheal Rai and Priyadarshini Samikumar will provide their playbook on several sectors from electronics to engineering, and why global giants should be looking closely at India and Tamil Nadu.

The authors of today’s issue of the India Rising Perspective - Inside the $1 Trillion Economy, are Ms Priyadarshini Samikumar, Associate Vice President (Exports) and Mr Godson George Micheal Rai, Manager (Investment Strategy, Business and Trade Intelligence).

Priyadarshini and Godson bring diverse corporate experience to their current roles at Guidance Tamil Nadu. Priyadarshini previously worked with Australia’s leading investment promotion agency, while Godson, with exceptional academics from University College London, has managed a $ 1.6 billion hedge fund portfolio.

Both are now closely involved with Guidance Tamil Nadu, the state’s investment promotion agency that bridges government and industry to help businesses establish a strong presence in Tamil Nadu.

Enjoy the third issue of our series!

Forged at the intersection of World-Class Healthcare, Deep Research, and Advanced Manufacturing

Part 3 of India Rising Perspective - Inside the $1 Trillion Economy
By Godson and Priyadarshini

Something remarkable has been unfolding in southern India. While global attention has focused on the technology corridors of Bengaluru or the financial hubs of Mumbai, a different kind of ecosystem has been maturing along the Coromandel Coast. Tamil Nadu, a state roughly the size of Greece, with a population exceeding Germany's, has emerged as one of India’s and Asia’s most sophisticated life sciences clusters. This is not a story of government ambition alone, nor simply of cost arbitrage. It is a story of how healthcare excellence, research depth, and manufacturing capability have converged to create something genuinely distinctive.

The evidence lies in the investment decisions of the world’s most discerning pharmaceutical companies. When AstraZeneca sought a location for its largest global capability centre larger than any facility in its Swedish or British homeland, it chose Chennai, the state capital. When Pfizer established its Global Drug Development Centre, it selected the IIT Madras Research Park. When Roche built out its clinical research operations for Asia, Tamil Nadu became the anchor.

These were not decisions made lightly. They reflect a recognition that this corner of India offers something increasingly rare: a complete life sciences value chain where the entire journey from research through clinical trials to commercial manufacturing can be executed within a single, well-integrated geography.

Tamil Nadu commands 40% of India's medical tourism, attracting 1.5 million patients annually from over 70 countries seeking treatment that combines world-class outcomes with accessible costs. Its doctor-to-patient ratio of 1:495 is the nation's highest, supported by one million registered medical professionals. The state maintains 77,532 government hospital beds and 12,500 private beds. Five JCI-accredited hospitals deliver tertiary care at costs 60–80% below Western equivalents, not through compromise, but through scale and efficiency. A cardiac bypass that costs $150,000 in the United States can be performed with equivalent outcomes for a fraction of that amount in Chennai, transforming the city into what many now call the 'Health Capital of Asia.'

With 39 government medical colleges, India's highest, Tamil Nadu produces over 12,000 MBBS (Bachelor of Medicine, Bachelor of Surgery) graduates annually. In the 2024–2025 National Institutional Ranking Framework, several Tamil Nadu institutions were in the top ten: Christian Medical College (CMC) Vellore ranked third nationally, Amrita Vishwa Vidyapeetham eighth, and Madras Medical College tenth.

Tamil Nadu's healthcare ecosystem rests on a foundation of pioneering institutions that have shaped medical practice and research in India for over a century.

CMC Vellore, founded in 1900, pioneered India's first open-heart surgery in 1961, first kidney transplant in 1971, and first bone marrow transplantation in 1986. Today, it handles over 9,000 patients daily and holds research partnerships with the Royal College of Surgeons Ireland, the US National Institutes of Health, and King's College London. The Cancer Institute at Adyar, South Asia's first dedicated oncology centre, established in 1954, collaborates with King's College London, the Royal College of Surgeons, and the Gates Foundation on cancer research and prevention.

The state has produced luminaries who shape global healthcare. Dr. Gagandeep Kang became the first Indian woman elected Fellow of the Royal Society of London. Dr. Mammen Chandy received the Padma Shri for pioneering stem cell transplantation. Apollo Hospitals, Rela Hospital, Sri Ramachandra Medical Centre, MGM Healthcare, and MIOT International have built Chennai's reputation as a destination where complex procedures meet world-class outcomes.

What distinguishes Tamil Nadu from other emerging life sciences destinations is the completeness of its ecosystem. Over 400 companies operate across pharmaceuticals, medical technology, and biotechnology, not as isolated entities but as an interconnected network spanning R&D, manufacturing, and clinical services. Pharmaceutical companies draw on local API manufacturers, medical device firms collaborate with hospital networks for clinical validation, and biotechnology ventures access both research institutions and manufacturing partners. Collectively, they have created over 50,000 high-quality jobs in the past three years, making Tamil Nadu India's fastest-growing destination for life sciences Global Capability Centres.

In pharmaceuticals, AstraZeneca's Chennai centre handles R&D data analysis, clinical operations, pharmacovigilance, and healthcare analytics. Pfizer focuses on small molecule technology, drug product design, and regulatory operations. Piramal Pharma, Caplin Point Laboratories, Sun Pharma, Natco Pharma, Solara Active Pharma Sciences, and Eurofins add depth across complex generics, sterile injectables, APIs, and analytical testing for EMA and FDA submissions.

In medical technology, Japan's Omron Healthcare has invested ₹128 crore (EUR 14.2 million) in its first Indian manufacturing facility, producing blood pressure monitors and cardiovascular devices from March 2025. Germany's B. Braun manufactures infusion therapy and surgical instruments. Medtronic operates diabetes care and surgical technology divisions. Trivitron Healthcare houses South Asia's first Labsystems Diagnostics IVD Factory through Indo-Finnish collaboration, manufacturing CE-certified equipment for global export. Perfint Healthcare develops robotic surgical systems. IQVIA runs clinical trial management. Twin Health applies AI to metabolic disease reversal.

The biotechnology cluster includes Biocon, India's largest biopharmaceutical company, alongside Teva, Bayer, and LifeCell International, which pioneered India's stem cell banking industry from Chennai. Kemin Industries manufactures health ingredients for global markets.

The affinity between European life sciences and Tamil Nadu runs deeper than commercial convenience. The India-EU Science and Technology Agreement, renewed through 2030 at the 14th Joint Steering Committee meeting in September 2024, specifically prioritises health and biotechnology research. Under Horizon Europe, collaborative projects in vaccine development and translational medicine are underway. The Trade and Technology Council creates institutional pathways for technology transfer and regulatory harmonisation. These frameworks reduce friction and provide predictability for long-term research partnerships.

Research collaborations demonstrate this intellectual alignment. IIT Madras partners with Macquarie University on synthetic biology, Boston University on diabetes research, and Louisiana State University on AI-powered cancer diagnostics. CMC Vellore works with the Royal College of Surgeons on clinical trials and medical education. VIT Vellore collaborates with Dankook University on tissue engineering and with NUS on medical technology commercialisation. These are substantive programmes producing peer-reviewed research and trained scientists fluent in both European and Indian contexts.

The European Commission's 2025 Life Science Strategy, positioning the EU as the world's most attractive life sciences destination by 2030, emphasises strengthening bioclusters and accelerating clinical trials. Tamil Nadu offers a natural complement: access to the world's largest clinical trial population, 60–80% cost advantages in R&D operations, and regulatory standards increasingly aligned with EMA requirements. Where Europe faces demographic pressures from aging populations, Tamil Nadu provides a young, growing market alongside manufacturing scale.

The state's healthcare infrastructure supports clinical research at scale: over 500 CT scanners, 150 MRI scanners, 30 PET-CT scanners, and 60 LINACs across major hospitals. This density of advanced medical equipment enables the sophisticated diagnostic and monitoring capabilities that modern clinical trials require.

The Tamil Nadu Medical Services Corporation India's first state-level procurement agency for generic drugs demonstrates the sophisticated institutional capacity that global companies require for large-scale partnerships. The Chief Minister's Comprehensive Health Insurance Scheme covers over 1,450 procedures, including organ transplants and cochlear implants, creating a healthcare market with genuine volume and institutional buyers.

A proposed 350-acre medical devices park at SIPCOT Oragadam will provide international-standard testing facilities for sensors, EMI/EMC, biomaterial compatibility, and radiation infrastructure designed specifically to meet European certification requirements. The Healthcare Technology Innovation Centre at IIT Madras serves as a collaborative platform bringing together engineers, clinicians, and industry. NITI Aayog has classified Tamil Nadu as a 'Performer' in the Fiscal Health Index 2025, specifically citing 'Quality of Expenditure' recognition that government investments translate efficiently into outcomes.

Over $22 billion in private equity and venture capital has flowed into India's life sciences sector since 2018, particularly in drug discovery, biotechnology, health technology, and digital health. The Contract Research, Development, and Manufacturing Organisation (CRDMO) sector has delivered 15% compound annual growth between 2019 and 2024, nearly double the global average. The global CDMO market, valued at $185 billion in 2024, is projected to reach $369 billion by 2034. Tamil Nadu is positioned to capture a disproportionate share of this growth, offering operational costs significantly below India's traditional business centres while maintaining superior infrastructure and the country's lowest talent attrition rates.

The pharmaceutical industry's post-pandemic reassessment of supply chain resilience has accelerated interest in diversifying manufacturing beyond traditional hubs. Tamil Nadu offers an attractive alternative: proven manufacturing capability, strong intellectual property protections, an English-speaking workforce, common law legal traditions, and timezone advantages enabling round-the-clock collaboration with European and American headquarters.

For global life sciences companies, the question is no longer whether to engage with India but where and how. Tamil Nadu has already provided the answer for Pfizer, Roche, AstraZeneca, Omron, and Medtronic. The state offers not merely cost advantages but strategic advantages: a healthcare ecosystem of genuine depth, research institutions of international calibre, regulatory alignment with global standards, and government partners who understand the pharmaceutical industry's requirements.

As global life sciences navigate the twin pressures of cost optimisation and innovation acceleration, Tamil Nadu presents a rare opportunity—a destination where both objectives can be achieved simultaneously. The infrastructure is built. The talent is available. The partnerships are proven. The ecosystem continues to mature with each new investment. The decisions of the world's leading pharmaceutical companies suggest that those closest to the industry have already drawn their conclusions. The question for others is simply one of timing.

Next in this series: A closer look at how the manufacturing sector develops in Tamil Nadu to support “Make in India”.

Sources: Guidance Tamil Nadu, NITI Aayog, The Hindu, European Commission

If you want to explore more on this topic or have questions, please reach out to the authors via LinkedIn:

Priyadarshini Samikumar, Godson George Micheal Rai

Disclaimer: Views expressed by authors are personal. Any use of the data or graphics require prior approval from Guidance Tamil Nadu.

Enjoyed this issue? Share India Rising with your network.

You can’t get enough or want to catch up on past editions? Follow the link!